Medistem Collaborates on Nanoparticle siRNA Finding for Treatment of Ischemic Conditions

Medistem Inc., a clinical stage adult stem cell company, reported today on a publication of a novel method of preventing transplant-associated ischemic liver injury using a nanotechnology delivery system that selectively targets hepatocytes.

Related Posts

Comments are closed.